FGF21 and Hepatic fibrosis: Pegbelfermin (BMS-986036), a PEGylated human FGF-21 analogue, which previously improved markers of liver fibrosis in obese patients with T2DM, was the subject of a phase II double-blind, randomized clinical trial.35 Patients with NASH with fibrosis staging 1–3 were allocated to pegbelfermin 10 mg once daily (n=25), pegbelfermin 20 mg once weekly (n=24) or placebo (n=26), stratified in 1:1:1 ratio and adjusted for diabetes status.